AD
15
2
3
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.3%
2 terminated out of 15 trials
71.4%
-15.1% vs benchmark
7%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection
Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders
The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction in Alzheimer's Disease
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807